Nanoform Finland Plc
May 20, 2021
09:10 p.m. Finnish time / 08:10 p.m. Swedish time
Cynthia Schwalm transitions to Senior Advisor Business Development US, from her role as member of the Board of Directors
Helsinki, Finland – As a consequence of the increasingly strong trend among large US institutional investors to demand that board members hold no more than four board positions in publicly listed companies, Cynthia Schwalm has today resigned from Nanoform’s board of directors. Cynthia will continue as a senior advisor to the CEO Edward Hæggström, with focus on US Business Development.
Cynthia Schwalm: “It’s been rewarding to serve on the Board of Nanoform. This move was necessitated by the strong trend in the US to have board members sit on fewer than five public company boards. Whilst Nanoform is a hugely exciting company with great potential for the future of healthcare this was the latest and fifth public company board I joined, therefore it is only fair to step down from the board of directors. In my new role as senior advisor to Nanoform, I’m delighted to be able to continue to support as needed and focus on business development and operational aspects. I look forward to be part of Nanoform’s exciting journey and to bring my years of experience and insights to help drive its proposition of “small is powerful” to patients in need, particularly in the United States.”
Edward Hæggström: “I very much look forward to continue to work with Cynthia in her new role as senior advisor to the CEO. Her clarity of thought and vast experience from the global pharma industry has been evident in her excellent board work at Nanoform.”
For further information, please contact:
Edward Haeggström, CEO
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
The information was sent for publication, through the agency of the contact persons set out above, on May 20, 2021, at 09:10 p.m. Finnish time / 08:10 p.m. Swedish time.
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information, please visit www.nanoform.com.